Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
Conclusions: There does not appear to be a relationship between adalimumab exposure and risk of adverse events in IBD patients.
PMID: 31144993 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
More News: Dermatology | Gastroenterology | Humira | Inflammatory Bowel Disease | PET Scan | Skin | Study